**Supplemental Table 1**. Published articles (July 2003 – August 2019) describing the 264 patients who developed hypophysitis after administration of a monoclonal antibody blocking CTLA-4, PD-1, or PD-L1.

*Case Reports (papers reporting only one hypophysitis patient)*

1. Shaw SA, Camacho LH, McCutcheon IE, Waguespack SG. Transient Hypophysitis after Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA4) Blockade. *J Clin Endocrinol Metab*, 92(4), 1201-1202 (2007).

2. Phan GQ, Yang JC, Sherry RM *et al.* Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci U S A*, 100(14), 8372-8377 (2003).

3. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. *Melanoma Res*, (2009).

4. Barnard ZR, Walcott BP, Kahle KT, Nahed BV, Coumans JV. Hyponatremia associated with Ipilimumab-induced hypophysitis. *Med Oncol*, (2011).

5. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman A. Ipilimumab: A novel Immunomodulating Therapy Causing Autoimmune Hypophysitis. A Case Rerport and Review. *Eur J Endocrinol*, (2012).

6. Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. *Cancer management and research*, 4, 299-307 (2012).

7. Schleder S. Ipilimumab-induzierte hypophysitis. *Fortschr Röntgenstr*, 185, 268-269 (2013).

8. van der Hiel B, Blank CU, Haanen JB, Stokkel MP. Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab. *Clinical nuclear medicine*, (2013).

9. Hihara K, Sato H, Okamoto I *et al.* Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer. *Auris Nasus Larynx*, (2019).

10. Anderson L, Bhatia V. Ipilimumab immune-related adverse reactions: a case report. *South Dakota medicine : the journal of the South Dakota State Medical Association*, 66(8), 315-317 (2013).

11. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. *Practical neurology*, 13(4), 278-280 (2013).

12. Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. *Journal of the National Comprehensive Cancer Network : JNCCN*, 12(8), 1077-1081 (2014).

13. Fischli S, Allelein S, Zander T, Henzen C. [Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies]. *Dtsch Med Wochenschr*, 139(19), 996-1000 (2014).

14. Majchel D, Korytkowski MT. Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review. *Case reports in endocrinology*, 2015, 570293 (2015).

15. Minor DR, Bunker SR, Doyle J. Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab. *J Clin Oncol*, 31(20), e356 (2013).

16. Pocha C, Roat J, Viskocil K. Immune-mediated colitis: important to recognize and treat. *J Crohns Colitis*, 8, 181-182 (2014).

17. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. *Arthritis & Rheumatol*, 66(3), 768-769 (2014).

18. Luke JJ, Callahan MK, Postow MA *et al.* Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. *Cancer*, 119(20), 3687-3695 (2013).

19. Danlos FX, Pages C, Roux J *et al.* Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. *Melanoma Res*, 25, 178-179 (2014).

20. Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. *J Endocrinol Invest*, (2015).

21. Kotwal A, Rao S, Haas RA. Ipilimumab-induced hypophysitis may not affect all pituitary cell lines: A case report. *J Endocrinol Metab*, 5(5), 299-303 (2015).

22. Boyd K, Kalladka D, Overell J, Waterston A. Ipilimumab Induced Encephalitis: A Case Report. *Immunome Res*, 11(2), 1-3 (2015).

23. Vancieri G, Bellia A, Lauro D. Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report. *J Endocrinol Invest*, (2016).

24. Marques P, Grossman A. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case. *Acta Médica Portuguesa*, 28(6), 775-779 (2015).

25. Subbiah V, Maiti A. Headache in a patient with renal cell carcinoma. *European journal of internal medicine*, (2016).

26. Johnson DB, Mudigonda TV, Sosman JA. Melanoma and a Headache. Diagnosis: Hypophysitis. *JAMA oncology*, 1(8), 1167-1168 (2015).

27. Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. *The Journal of dermatology*, (2016).

28. Ohnuma T, Matsuzawa T, Kinoshita M *et al.* Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis. *The Journal of dermatology*, (2016).

29. Okano Y, Satoh T, Horiguchi K *et al.* Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. *Endocr J*, 63(10), 905-912 (2016).

30. Caturegli P, Di Dalmazi G, Lombardi M *et al.* Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. *Am J Pathol*, 186(12), 3225-3235 (2016).

31. Koessler T, Olivier T, Fertani S, Marinari E, Dutoit V, Dietrich PY. Ipilimumab-related hypophysitis may precede severe CNS immune attack. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*, 27(10), 1975-1976 (2016).

32. Wilson MA, Guld K, Galetta S *et al.* Acute visual loss after ipilimumab treatment for metastatic melanoma. *Journal for immunotherapy of cancer*, 4, 66 (2016).

33. Wachsmann JW, Ganti R, Peng F. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. *Academic radiology*, 24(1), 111-115 (2017).

34. Singh D, Hsu CC, Kwan GN, Bhuta S. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings. *Neurol India*, 65(1), 165-166 (2017).

35. Chang LS, Yialamas MA. Checkpoint Inhibitor-Associated Hypophysitis. *Journal of general internal medicine*, 33(1), 125-127 (2018).

36. Takaya K, Sonoda M, Fuchigami A, Hiyoshi T. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. *Intern Med*, 56(18), 2463-2469 (2017).

37. Valecha G, Pant M, Ibrahim U, Atallah JP. Immunotherapy-induced autoimmune hypophysitis. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, 1078155217727142 (2017).

38. Seki T, Yasuda A, Oki M *et al.* Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. *The Tokai journal of experimental and clinical medicine*, 42(3), 115-120 (2017).

39. Kuru S, Khan N, Shaaban H. Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. *International journal of critical illness and injury science*, 7(3), 177-180 (2017).

40. Marchand L, Paulus V, Fabien N *et al.* Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 12(11), e182-e184 (2017).

41. Ohara N, Ohashi K, Fujisaki T *et al.* Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. *Intern Med*, 57(4), 527-535 (2018).

42. Tanaka F, Kogue R, Maeda M *et al.* Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery. *Radiology case reports*, 13(1), 261-264 (2018).

43. Hassanzadeh B, DeSanto J, Kattah JC. Ipilimumab-induced Adenohypophysitis and Orbital Apex Syndrome: Importance of Early Diagnosis and Management. *Neuro-ophthalmology (Aeolus Press)*, 42(3), 176-181 (2018).

44. Zhao C, Tella SH, Del Rivero J *et al.* Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. *J Clin Endocrinol Metab*, 103(2), 365-369 (2018).

45. Pucar D, Boustani AM, Bronen RA, Saperstein L. Superior Pituitary Border Analysis in Immunotherapy-Induced Hypophysitis. *Clinical nuclear medicine*, 43(4), 284-286 (2018).

46. Ileana-Dumbrava E, Subbiah V. Autoimmune hypophysitis. *The lancet oncology*, 19(2), e123 (2018).

47. Sum M, Garcia FV. Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis. *Pituitary*, 21(5), 556-557 (2018).

48. Gunawan F, George E, Roberts A. Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. *Endocrinology, diabetes & metabolism case reports*, 2018 (2018).

49. Cheema A. Ipilimumab-induced Secondary Hypophysitis. *Endocr Pract*, (2018).

50. Tsukizawa Y, Kondo K, Ichiba T, Naito H, Mizuki K, Masuda K. Refractory hypotension due to Nivolumab-induced adrenal insufficiency. *Nagoya journal of medical science*, 80(2), 285-288 (2018).

51. Wallace J, Krupa M, Brennan J, Mihlon F. Ipilimumab cystic hypophysitis mimicking metastatic melanoma. *Radiology case reports*, 13(3), 740-742 (2018).

52. Gambale E, Tinari C, Carella C, Di Paolo A, De Tursi M. Immunotherapy and hypophysitis in the clinical practice: A case report. *J Clin Case Rep*, 6(9), 1-3 (2016).

53. Jaafar J, Phillippe J. Anti-CTLA-4 monoclonal antibodies induced hypophysitis: case report and literature review. *Annals Clin Case Reports - Pediatrics*, 2(1382), 1-8 (2017).

54. Velasco Acuna MJ, Shoukri K. Ipilimumab cuasing autoimmune hypophysitis: a case report. *Endocrinology Diabetes and Obesity*, 1(1), 1-5 (2018).

55. Zeng MF, Chen LL, Ye HY *et al.* Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review. *Medicine (Baltimore)*, 96(44), e8426 (2017).

56. Zhu Y, Wu HH, Wang W. A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab. *OncoTargets and therapy*, 12, 2181-2186 (2019).

57. Mishima Y, Fukaishi T, Inase N, Isogai S. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma: A Case Report. *Internal Medicine*, 1-5 (2018).

58. Placais L, Hau E, Delyon J *et al.* Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis. *Melanoma Res*, 29(2), 205-207 (2019).

59. Chang J, Tran J, Kamel D, Basu A. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. *BMJ case reports*, 12(3) (2019).

60. Kastrisiou M, Kostadima FL, Kefas A *et al.* Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. *ESMO open*, 2(4), e000217 (2017).

61. Shrotriya S, Rai MP, Alratroot A, Sarzynski E. Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). *BMJ case reports*, 2018 (2018).

62. Takeno A, Yamamoto M, Morita M *et al.* Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. *BMC endocrine disorders*, 19(1), 25 (2019).

63. Sakaguchi C, Yano S, Ashida K *et al.* A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. *The American journal of case reports*, 20, 106-110 (2019).

64. Okahata S, Sakamoto K, Mitsumatsu T *et al.* Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. *Endocr J*, 66(4), 295-300 (2019).

65. Oristrell G, Baneras J, Ros J, Munoz E. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. *European heart journal. Case reports*, 2(2), yty038 (2018).

66. Saijo T, Tanaka A, Ito T, Ikeda N. A case of secondary adrenocortical insufficiency developed due to ACTH deficiency after nivolumab treatment. *Lung Cancer*, 57, 226-231 (2017).

67. Erra A, Pannu BS, Ptel S, Qureshi F, Soliman M. A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism. *Cureus*, 11(6), 55001 (2019).

68. Narahira A, Yanagi T, Cho KY *et al.* Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. *The Journal of dermatology*, 44(4), e70 (2017).

69. Fujimura T, Kambayashi Y, Furudate S *et al.* Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. *The Journal of dermatology*, 44(3), e13-e14 (2017).

70. Oda T, Sawada Y, Okada E *et al.* Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment. *The Journal of dermatology*, 44(6), e144-e145 (2017).

71. Shimizu Y, Tanemura A, Kotobuki Y, Katayama I, Okita T, Mukai K. Hypophysitis induced by ipilimumab in malignant melanoma patient. *Skin Research*, 17(5), 260-264 (2019).

72. Albarel F, Castinetti F, Brue T. Management of endocrine diseases: Immune check point inhibitors-induced hypophysitis. *Eur J Endocrinol*, 181(3), R107-r118 (2019).

73. Sekizaki T, Kameda H, Oba C *et al.* Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. *Endocr J*, (2019).

74. Davies A, Naderpoor N, Parakh S. Isolated Hypogonadotropic Hypogonadism Secondary to Anti-Programmed Death Ligand 1 Inhibitor. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 14(7), e147-e148 (2019).

75. Furubayashi N, Negishi T, Uozumi T *et al.* Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. *Molecular and clinical oncology*, 10(2), 304-308 (2019).

76. Sato Y, Tanaka Y, Hino M, Seike M, Gemma A. A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. *Respiratory medicine case reports*, 26, 223-226 (2019).

77. Lou Y, Marin-Acevedo JA, Vishnu P *et al.* Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. *Immunotherapy*, 11(7), 577-584 (2019).

78. Ito K, Uchida T, Manabe Y *et al.* A case of nivolumab-induced isolated adrenocorticotropic hormone deficiency presenting dyspnea. *Hinyokika kiyo. Acta urologica Japonica*, 64, 391-395 (2018).

79. Takebayashi K, Ujiie A, Kubo M *et al.* Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. *Journal of clinical medicine research*, 10(4), 358-362 (2018).

80. Iadarola C, Croce L, Quaquarini E *et al.* Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis. *Frontiers in endocrinology*, 9, 813 (2018).

81. Ariyasu H, Inaba H, Ota T *et al.* Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. *In Vivo*, 32(2), 345-351 (2018).

82. Mencel J, Gargett T, Karanth N, Pokorny A, Brown MP, Charakidis M. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma. *Asia Pac J Clin Oncol*, (2019).

83. Pierrard J, Petit B, Lejeune S, Seront E. Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barre syndrome occurring in a patient treated with nivolumab. *BMJ case reports*, 12(8) (2019).

84. Lanzolla G, Coppelli A, Cosottini M, Del Prato S, Marcocci C, Lupi I. Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. *Journal of the Endocrine Society*, 3(2), 496-503 (2019).

85. Yamagata S, Kageyama K, Takayasu S *et al.* Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. *Intern Med*, (2019).

86. Boudjemaa A, Rousseau-Bussac G, Monnet I. Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 13(3), e39-e40 (2018).

87. Martins Machado C, Almeida Santos L, Barroso A, Oliveira MJ. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. *BMJ case reports*, 12(8) (2019).

88. Ohara N, Kobayashi M, Ohashi K *et al.* Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. *Journal of medical case reports*, 13(1), 88 (2019).

*Case Series (papers reporting more than one hypophysitis patient: between 2 and 19)*

1. Blansfield JA, Beck KE, Tran K *et al.* Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. *J Immunother*, 28(6), 593-598 (2005).

2. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-Induced Hypophysitis: MR Imaging Findings. *AJNR Am J Neuroradiol*, (2009).

3. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. *Pituitary*, 13, 29-39 (2010).

4. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. *AJR Am J Roentgenol*, 197(6), W992-W1000 (2011).

5. Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. *Endocr Pract*, 18(3), 351-355 (2012).

6. Thomsen HH. Lymfocutaer hypofysitis pa baggrung af behandling med ipilimumab. *Ugeskr Laeger*, 174, 26-33 (2012).

7. Assi H, Wilson KS. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. *Current oncology (Toronto, Ont.)*, 20(2), e165-169 (2013).

8. de Hollanda A, Aranda GB, Mora M, Gaba L, Halperin I. Ipilimumab, a cause of autoimmune hypophysitis. *Endocrinol Nutr*, (2013).

9. Lammert A, Schneider HJ, Bergmann T *et al.* Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy. *Exp Clin Endocrinol Diabetes*, (2013).

10. Voskens CJ, Goldinger SM, Loquai C *et al.* The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PloS one*, 8(1), e53745 (2013).

11. Albarel F, Gaudy C, Castinetti F *et al.* Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. *Eur J Endocrinol*, (2014).

12. Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM. Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis. *Clin Neurol Neurosurg*, 125c, 125-130 (2014).

13. De Sousa SM, Long GV, Tonks KT. Ipilimumab-induced hypophysitis: early Australian experience. *The Medical journal of Australia*, 201(4), 198-199 (2014).

14. Faje AT, Sullivan R, Lawrence D *et al.* Ipilimumab-induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients with Metastatic Melanoma. *J Clin Endocrinol Metab*, jc20142306 (2014).

15. Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. *Endocrine*, (2014).

16. Rodrigues BT, Otty Z, Sangla K, Shenoy VV. Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions. *Endocrinology, diabetes & metabolism case reports*, 2014, 140098 (2014).

17. Cheng R, Cooper A, Kench J *et al.* Ipilimumab-induced toxicities and the gastroenterologist. *Journal of gastroenterology and hepatology*, (2015).

18. Heaney AP, Sumerel B, Rajalingam R, Bergsneider M, Yong WH, Liau LM. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. *J Clin Endocrinol Metab*, 100(11), 4092-4097 (2015).

19. Lam T, Chan MM, Sweeting AN *et al.* Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. *Intern Med J*, (2015).

20. Mahzari M, Liu D, Arnaout A, Lochnan H. Immune Checkpoint Inhibitor Therapy Associated Hypophysitis. *Clin Med Insights Endocrinol Diabetes*, (1179-5514 (Print)) (2015).

21. Tiu C, Pezaro C, Davis ID, Grossmann M, Parente P. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management. *Asia Pac J Clin Oncol*, (1743-7563) (2015).

22. Wyluda EJ, Cheng J, Schell TD *et al.* Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. *Cancer Biol Ther*, 16(5), 662-670 (2015).

23. Miller AH, Brock P, Jim Yeung SC. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department. *Annals of emergency medicine*, 68(2), 249-250 (2016).

24. Ariyasu R, Horiike A, Yoshizawa T *et al.* Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. *Anticancer research*, 37(8), 4229-4232 (2017).

25. Brilli L, Danielli R, Ciuoli C *et al.* Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. *Endocrine*, (2017).

26. Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]. *Endocr J*, 64(2), 235-236 (2017).

27. Kitajima K, Ashida K, Wada N *et al.* Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. *Japanese journal of clinical oncology*, 1-4 (2017).

28. Otsubo K, Nakatomi K, Furukawa R *et al.* Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*, 28(12), 3106-3107 (2017).

29. Wadhwa V. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases. *J Ark Med Soc*, 113(11), 270-272 (2017).

30. De Sousa SMC, Sheriff N, Tran CH *et al.* Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. *Pituitary*, 21(3), 274-282 (2018).

31. Kanie K, Iguchi G, Bando H *et al.* Two Cases of Atezolizumab-Induced Hypophysitis. *Journal of the Endocrine Society*, 2(1), 91-95 (2018).

32. Kitano S, Tatsuno K, Ishibe J *et al.* Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab. *Acta Derm Venereol*, 98(7), 704-705 (2018).

33. Lin CH, Chen KH, Chen KY, Shih SR, Lu JY. Immune checkpoint inhibitor therapy-induced hypophysitis approximately a case series of Taiwanese patients. *J Formos Med Assoc*, (2018).

34. Malikova H, Holesta M, Fialova A, Arenbergerova M, Weichet J. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors treatment: Spectrum of imaging appearances. *Neuro Endocrinol Lett*, 39(3), 196-204 (2018).

35. Nagasaka M, Abdallah N, Samantray J, Sukari A. Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. *Clinical case reports*, 6(7), 1278-1281 (2018).

36. Snyders T, Chakos D, Swami U *et al.* Ipilimumab-induced hypophysitis, a single academic center experience. *Pituitary*, (2019).

37. Wei kZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. *Melanoma Manag*, (2019).

38. Inaba H, Ariyasu H, Iwakura H *et al.* Comparative analysis of HLA between Idiopathic and Anti-PD-1 antibody induced Isolated ACTH deficiency: A Pilot Study. *Clin Endocrinol (Oxf)*, (2019).